

## ORIGINAL

# Antimicrobial resistance properties of *Helicobacter pylori* strains isolated from dental plaque and saliva samples

*Propiedades de resistencia antimicrobiana de cepas de Helicobacter pylori aisladas de muestras de placa dental y saliva*

Amirhossein Fathi<sup>1</sup> , Ashkan Salehi<sup>2</sup> 

1. Dental Material Research Center, Department of Prosthodontics, Isfahan University of Medical Sciences, Isfahan, Iran

2. Department of Dentistry, University of Traditional Medicine of Armenia (UTMA), Armenia

## Corresponding authors

Ashkan Salehi

Department of Dentistry, University of Traditional Medicine of Armenia (UTMA), Armenia

E-mail: ashkansalehip@gmail.com

Received: 13 - IX - 2021

Accepted: 7 - XI - 2021

doi: 10.3306/AJHS.2022.37.01.29

## Abstract

**Background:** It is likely that oral cavity, particularly dental plaque and saliva samples, may represent an important reservoir of *H. pylori* infection for gastric infections. The present research was performed to assess the distribution and antimicrobial resistance of *H. pylori* strains in dental plaque and saliva samples.

**Methods:** A total of 80 *H. pylori* strains were isolated from dental plaque (n= 42) and saliva (n= 38) samples of patients referred to the Dental Clinic of the Armenia for routine check-ups. *H. pylori* was isolated using culture. Antimicrobial resistance was determined using disk diffusion.

**Results:** Twenty-two out of 80 (27.50%) examined specimens were positive for *H. pylori*. *H. pylori* prevalence amongst dental plaque and saliva samples was 33.33% and 21.05%, respectively (P <0.05). *H. pylori* strains harbored the high prevalence of resistance against ampicillin (77.27%), amoxicillin (72.22%), erythromycin (68.18%), and tetracycline (68.18%), Resistance rate toward metronidazole was lower than other antimicrobials (40.90%).

**Conclusion:** The role of dental plaque and saliva samples as *H. pylori* reservoirs was determined. Due to the high antimicrobial resistance of isolates against ampicillin, amoxicillin, erythromycin, tetracycline, and even metronidazole, there is a big demand for substitute antimicrobials for the oral colonized *H. pylori*.

**Keywords:** *Helicobacter pylori*, dentalplaque, saliva, prevalence, antimicrobial resistance.

## Resumen

**Antecedentes:** Es probable que la cavidad oral, en particular la placa dental y las muestras de saliva, puedan representar un importante reservorio de *H. pylori* para las infecciones gástricas. La presente investigación se realizó para evaluar la distribución y la resistencia antimicrobiana de las cepas de *H. pylori* en la placa dental y las muestras de saliva.

**Métodos:** Se aislaron un total de 80 cepas de *H. pylori* de muestras de placa dental (n= 42) y saliva (n= 38) de pacientes remitidos a la Clínica Dental de Armenia para revisiones rutinarias. El *H. pylori* se aisló mediante cultivo. La resistencia a los antimicrobianos se determinó mediante difusión en disco.

**Resultados:** Veintidós de las 80 muestras examinadas (27,50%) fueron positivas para *H. pylori*. La prevalencia de *H. pylori* en las muestras de placa dental y saliva fue del 33,33% y el 21,05%, respectivamente (P <0,05). Las cepas de *H. pylori* presentaban una alta prevalencia de resistencia a la ampicilina (77,27%), la amoxicilina (72,22%), la eritromicina (68,18%) y la tetraciclina (68,18%).

**Conclusión:** Se determinó el papel de las muestras de placa dental y saliva como reservorios de *H. pylori*. Debido a la elevada resistencia antimicrobiana de los aislados frente a la ampicilina, la amoxicilina, la eritromicina, la tetraciclina e incluso el metronidazol, existe una gran demanda de antimicrobianos sustitutos para el *H. pylori* colonizado por vía oral.

**Palabras clave:** *Helicobacter pylori*, placa dental, saliva, prevalencia, resistencia antimicrobiana.

## Introduction

The oral cavity is the primary way for the entrance of foods into the body. As the oral cavity is the entry port and first component of the gastrointestinal system, researchers have been interested in the presence of some kinds of bacteria in this niche<sup>1</sup>. Both dental plaque and saliva samples can be infected with diverse kinds of bacteria responsible for digestive infections and disorders<sup>2</sup>. There are a few studies in the literature claiming to have isolated the *Helicobacter pylori* (*H. pylori*) from dental plaque and saliva samples<sup>3</sup>.

*Helicobacter pylori* (*H. pylori*) is a microaerophilic and coccoid, and spiral bacterium recognized as a reason of gastric adenocarcinoma, peptic ulcer disease, duodenal ulcer, type B gastritis, and B-cell lymphoma<sup>4-7</sup>. Even though the human stomach is considered the main *H. pylori* reservoir<sup>8</sup>, it was routinely identified in the oral cavity, particularly dental plaques, saliva, tongue, root canals, tonsil tissue, and oral mucosa<sup>9</sup>. It has been suggested that the *H. pylori* fermenting carbohydrates in food produce a low pH in the oral cavity, and this microaerophilic acidic environment with an average oral temperature of 35-37°C can be ideal for its growth and survival<sup>10,11</sup>.

Infections caused by *H. pylori* are mainly treated with antimicrobial therapies<sup>12</sup>. However, recent surveys have shown the high *H. pylori* resistance rate toward commonly prescribed antimicrobial agents<sup>13</sup>. In this regard, the highest resistance rate was observed against specific antimicrobials and choices of the oral and gastrointestinal infections, particularly ampicillin, amoxicillin, metronidazole and clarithromycin<sup>14,15</sup>. Changes in the antimicrobial administration and prescription caused severe changes in the *H. pylori*'s resistance pattern during the time<sup>16</sup>. Thus, it is essential to assess the antimicrobial resistance of *H. pylori* strains to determine the exact bacterial manner and antimicrobial choices.

Rendering to the uncertain role of dental plaque and saliva samples as a reservoir of antibiotic-resistant *H. pylori* strains, the present survey was aimed to assess the antimicrobial resistance of *H. pylori* strains isolated from dental plaque and saliva samples of patients referred to the Armenia dental clinics for the routine check-up.

## Materials and methods

### Samples

From January 2020 to March 2021, a total of 80 *H. pylori* strains were isolated from dental plaque (n=42) and saliva (n=38) samples of patients referred to the Dental Clinic of the Armenia for routine check-ups.

### *H. pylori* isolation and identification

The dental plaque and saliva specimens from each

patient was cultured into a sterile tube containing 5% sheep blood agar, chocolate agar, and a selective medium and transported to the microbiology laboratory to be incubated microaerophilically (5% oxygen, 85% nitrogen, and 10% CO<sub>2</sub>) using the MART system (MART system, Lichtenvoorde, The Netherland) at a temperature of 37°C for seven days. Culture media were supplemented with 5% of horse serum (Sigma, St. Louis, MO, USA), nalidixic acid (30 mg/L), vancomycin (10 mg/L), cycloheximide (100 mg/L), and trimethoprim (30 mg/L) (Sigma, St. Louis, MO, USA). Suspected colonies were then identified using Gram stain, motility, colony morphology, and biochemical tests such as urease, oxidase, and catalase tests. For comparison, a reference strain of *H. pylori* (ATCC 43504) was employed<sup>17</sup>.

### Antimicrobial resistance

Mueller–Hinton agar (Merck, Germany) assessed antibiotic resistance patterns using the simple disk diffusion technique. Antibiotic resistance profile of *H. pylori* bacteria was researched toward different antibiotic against (Oxoid, UK) using the guidelines of previous research<sup>18</sup> and also those of Performance Standards for Antimicrobial Susceptibility Testing- Clinical and Laboratory Standards Institute - NCCLS, 2007<sup>19</sup>. Bacterial suspensions were adjusted to the 0.5 McFarland standard (equivalent to 1–2 × 10<sup>8</sup> CFU/mL) and inoculating Muller Hinton agar plates (Merck, Germany). The resistance of bacteria was examined toward metronidazole (5 µg), ampicillin (10 µg), tetracycline (30 µg), clarithromycin (2 µg), erythromycin (5 µg), and amoxicillin (10 µg) (Oxoid, UK). Antibiotic disks were placed on media contained the bacteria, and the plates were incubated under microaerophilic conditions at 35°C for 16-18 h. The zones of growth inhibition produced by each antibiotic were measured and interpreted by standard procedure.

### Data analysis

Data were subjected to Microsoft Office Excel (version 15; Microsoft Corp., Redmond, WA, USA). The statistical analysis was performed employing the SPSS 21.0 software (SPSS Inc., Chicago, IL, USA). Chi-square test and Fisher's exact two-tailed test were applied to measure any significant relationship. *P*-value <0.05 was considered as a significant numerical level<sup>20-25</sup>.

## Results

### *H. pylori* distribution

**Table I** shows the *H. pylori* distribution amongst the studied population. Twenty-two out of 80 (27.50%) examined specimens were positive for *H. pylori*. *H. pylori* distribution amongst dental plaque and saliva samples was 33.33% and 21.05%, respectively. A statistically significant difference was obtained for the *H. pylori* distribution between dental plaque and saliva specimens (*P* <0.05).

**Table I:** *H. pylori* distribution amongst the studied population.

Specimens	N. specimens collected	N. specimens positive for <i>H. pylori</i> (%)
Dental plaque	42	14 (33.33)
Saliva	38	8 (21.05)
Total	80	22 (27.50)

### *H. pylori* antimicrobial resistance

**Table II** shows the antimicrobial resistance of *H. pylori* strains isolated from dental plaque and saliva specimens. *H. pylori* strains isolated from examined specimens harbored the high prevalence of resistance against ampicillin (77.27%), amoxicillin (72.22%), erythromycin (68.18%), and tetracycline (68.18%), antimicrobials. Resistance rate toward metronidazole was lower than other antimicrobials (40.90%). *H. pylori* isolates of dental plaque samples had a higher prevalence of resistance toward all examined antimicrobial agents ( $P < 0.05$ ).

## Discussion

Notwithstanding an enormous expansions in medicine, varied complicated infectious diseases faced with the human<sup>26-30</sup>. In this regard, *H. pylori* have become a developed public health issue in the last century<sup>31</sup>.

*H. pylori* prevalence among the dental plaque and saliva specimens was 33.33% and 21.05%, respectively. Higher *H. pylori* prevalence in saliva than dental plaque specimens was also reported from Japan<sup>32</sup>, Mexico (33), Malaysia<sup>34</sup>, Iran<sup>35</sup>, and Peru<sup>36</sup>. Yang et al. (2015) (37) showed that 76% of dental plaque samples collected in China were positive for *H. pylori*. Rasmussen et al. (2010)<sup>38</sup> stated that the *H. pylori* prevalence amongst the saliva and dental plaque samples was 42.30% and 47.40%, respectively. However, these is no strict data about the exact source of *H. pylori* in dental plaque and saliva samples. Maybe foods have the main role in transmission of *H. pylori* into the oral cavity and then stomach.

*H. pylori* isolates of dental plaque and saliva samples harbored the high resistance rate toward ampicillin, tetracycline, amoxicillin, erythromycin, and clarithromycin. These antimicrobials are the major therapeutic options used for *H. pylori* eradication, particularly in the mouth,

among Iranian practitioners. High and illegal antibiotic prescriptions in medical and dental clinics and excessive use of disinfectants and mouthwashes solutions may cause the high antimicrobial resistance observed in the present survey. Our findings showed the higher antimicrobial resistance of *H. pylori* strains isolated from dental plaque than saliva samples. This finding may be due to the biofilm formation of *H. pylori* strains in the dental plaque samples<sup>39</sup>. Hanafiah et al. (2019)<sup>40</sup> reported that resistance rates of *H. pylori* strain to metronidazole and clarithromycin antimicrobial agents were 59.30%, and 35.6%, respectively. Mashak et al. (2020)<sup>41</sup> reported that the resistance rates of *H. pylori* strains against ampicillin, clarithromycin, erythromycin, metronidazole, levofloxacin, tetracycline, amoxicillin, rifampin, trimethoprim, cefsulodin, streptomycin, furazolidone, and spiramycin antimicrobial agents were 59.61%, 61.53%, 80.76%, 51.92%, 63.46%, 82.69%, 63.46%, 40.38%, 65.38%, 38.46%, 59.61%, 25.00%, and 21.15%, respectively.

Totally, this survey is the first report of identification of antimicrobial resistance of *H. pylori* strains isolated from dental plaque and saliva samples in Armenia. Findings are limited to the low number of isolated bacteria, lack of demographical characters of the studied population and also absence of the determination of the history of gastrointestinal disorders among patients.

## Conclusion

To sum it up, diverse antimicrobial resistance was found in the *H. pylori* strains isolated from dental plaque and saliva samples. Ampicillin, amoxicillin, clarithromycin, tetracycline, erythromycin and even metronidazole antimicrobials were not effective against isolates. *H. pylori* isolates of dental plaque samples harbored the higher antimicrobial resistance. This finding may show the predominant role of dental plaque samples as a reservoir of antimicrobial-resistant *H. pylori*. Additionally, findings may suggest that the oral cavity, particularly dental plaque and saliva samples, may be a *H. pylori* reservoir and potentially a source of transmission or reinfection.

## Interests conflict

The researchers declare that they have no conflict of interest.

**Table II:** Antimicrobial resistance of *H. pylori* strains isolated from dental plaque and saliva specimens.

Specimens (N. positive)	N. <i>H. pylori</i> isolates harbored resistance against each antimicrobial agents (%)					
	Cir*	Ert	Amx	Amp	Tet	Met
Dental plaque (14)	10 (71.42)	10 (71.42)	11 (78.57)	12 (58.71)	10 (71.42)	7 (50.00)
Saliva (8)	4 (50.00)	5 (62.50)	5 (62.50)	5 (62.50)	5 (62.50)	2 (25.00)
Total (22)	14 (63.63)	15 (68.18)	16 (72.72)	17 (77.27)	15 (68.18)	9 (40.90)

\*Cir: clarithromycin (2 µg), Ert: erythromycin (5 µg), Amx: amoxicillin (10 µg), Amp: ampicillin (10 µg), Tet: tetracycline (30 µg), Met: metronidazole (5 µg).

## References

- Czesnikiewicz-Guzik M, Bielanski W, Guzik TJ, Loster B, Konturek SJ. *Helicobacter pylori* in the oral cavity and its implications for gastric infection, periodontal health, immunology and dyspepsia. *Journal of physiology and pharmacology*. 2005 Dec 1;56:77.
- Sarmah R, Khan RA, Devi KR. Microbes in human oral cavity: a review. *Reviews in Medical Microbiology*. 2021 Apr 1;32(2):75-82.
- Bicak DA, Akyuz S, Kiratlı B, Usta M, Urganci N, Alev B, Yarat A, Sahin F. The investigation of *Helicobacter pylori* in the dental biofilm and saliva samples of children with dyspeptic complaints. *BMC oral health*. 2017 Dec;17(1):1-2.
- Yahaghi E, Khamesipour F, Mashayekhi F, Safarpour Dehkordi F, Sakhaei MH, Masoudimanesh M, Khameneie MK. *Helicobacter pylori* in vegetables and salads: genotyping and antimicrobial resistance properties. *BioMed Research International*. 2014 Jan 1;2014.
- Ranjbar R, Yadollahi Farsani F, Safarpour Dehkordi F. Antimicrobial resistance and genotyping of *vacA*, *cagA*, and *iceA* alleles of the *Helicobacter pylori* strains isolated from traditional dairy products. *Journal of Food Safety*. 2019 Apr;39(2):e12594.
- Atapoor S, Dehkordi FS, Rahimi E. Detection of *Helicobacter pylori* in various types of vegetables and salads. *Jundishapur Journal of Microbiology*. 2014 May;7(5).
- Ranjbar R, Farsani FY, Dehkordi FS. Phenotypic analysis of antibiotic resistance and genotypic study of the *vacA*, *cagA*, *iceA*, *oipA* and *babA* genotypes of the *Helicobacter pylori* strains isolated from raw milk. *Antimicrobial Resistance & Infection Control*. 2018 Dec;7(1):1-4.
- Al Sayed A, Anand PS, Kamath KP, Patil S, Preethanath RS, Anil S. Oral cavity as an extragastric reservoir of *Helicobacter pylori*. *International Scholarly Research Notices*. 2014;2014.
- Singhal S, Dian D, Keshavarzian A, Fogg L, Fields JZ, Farhadi A. The role of oral hygiene in inflammatory bowel disease. *Digestive diseases and sciences*. 2011 Jan;56(1):170-5.
- Yee JK. *Helicobacter pylori* colonization of the oral cavity: A milestone discovery. *World Journal of Gastroenterology*. 2016;22(2):641.
- Yee JK. Are the view of *Helicobacter pylori* colonized in the oral cavity an illusion?. *Experimental & Molecular Medicine*. 2017;49(11):e397-.
- Goderska K, Pena SA, Alarcon T. *Helicobacter pylori* treatment: antibiotics or probiotics. *Applied microbiology and biotechnology*. 2018 Jan;102(1):1-7.
- Mousavi S, Dehkordi FS. Virulence factors and antibiotic resistance of *Helicobacter pylori* isolated from raw milk and unpasteurized dairy products in Iran. *Journal of Venomous Animals and Toxins including Tropical Diseases*. 2015 Jan 20;20:1-7.
- Ghorbani F, Gheisari E, Dehkordi FS. Genotyping of *vacA* alleles of *Helicobacter pylori* strains recovered from some Iranian food items. *Tropical Journal of Pharmaceutical Research*. 2016 Sep 5;15(8):1631-6.
- Mashak Z, Jafariaskari S, Alavi I, Shahreza MS, Dehkordi FS. Phenotypic and genotypic assessment of antibiotic resistance and genotyping of *vacA*, *cagA*, *iceA*, *oipA*, *cagE*, and *babA2* alleles of *Helicobacter pylori* bacteria isolated from raw meat. *Infection and drug resistance*. 2020;13:257.
- Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW, Lee CL, Chen KY, Chuah SK. Trend of changes in antibiotic resistance in *Helicobacter pylori* from 2013 to 2019: a multicentre report from Taiwan. *Therapeutic Advances in Gastroenterology*. 2020 Dec;13:1756284820976990.
- Sudhakar U, Anusuya CN, Ramakrishnan T, Vijayalakshmi R. Isolation of *Helicobacter pylori* from dental plaque: A microbiological study. *Journal of Indian Society of Periodontology*. 2008;12(3):67.
- Andrews J. BSAC disc diffusion method for antimicrobial susceptibility testing. 2.1.4 ed. British Society for Antimicrobial Chemotherapy: Birmingham, UK; 2003.
- NCCLS. Performance Standards for Antimicrobial Susceptibility Testing. Approved Standard M7-A5: Informational Supplement M100- S18. National Committee for Clinical Laboratory Standards: Wayne, PA; 2007.
- Ranjbar R, Seif A, Dehkordi FS. Prevalence of antibiotic resistance and distribution of virulence factors in the shiga toxinogenic *Escherichia coli* recovered from hospital food. *Jundishapur Journal of Microbiology*. 2019;12(5):8.
- Nejat S, Momtaz H, Yadegari M, Nejat S, Safarpour Dehkordi F, Khamesipour F. Seasonal, geographical, age and breed distributions of equine viral arteritis in Iran. *Kafkas Univ Vet Fak Derg*. 2015 Jan 1;21(1):111-6.
- Dehkordi FS, Saberian S, Momtaz H. Detection and segregation of *Brucella abortus* and *Brucella melitensis* in Aborted Bovine, Ovine, Caprine, Buffaloes and Camelid Fetuses by application of conventional and real-time polymerase chain reaction. *The Thai Journal of Veterinary Medicine*. 2012 Mar 1;42(1):13.
- Rahimi E, Yazdanpour S, Dehkordi FS. Detection of *Toxoplasma gondii* antibodies in various poultry meat samples using enzyme linked immuno sorbent assay and its confirmation by polymerase chain reaction. *J Pure Appl Microbiol*. 2014;8(1):421-7.
- Dehkordi FS. Prevalence study of Bovine viral diarrhea virus by evaluation of antigen capture ELISA and RT-PCR assay in Bovine, Ovine, Caprine, Buffalo and Camel aborted fetuses in Iran. *AMB express*. 2011 Dec;1(1):1-6.
- Dehkordi FS, Haghghi N, Momtaz H, Rafsanjani MS, Momeni M. Conventional vs real-time PCR for detection of bovine herpes virus type 1 in aborted bovine, buffalo and camel foetuses. *Bulgarian Journal of Veterinary Medicine*. 2013 Jun 1;16(2).
- Mirzaie A, Halaji M, Dehkordi FS, Ranjbar R, Noorbazargan H. A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19). *Complementary therapies in clinical practice*. 2020 Aug 1;40:101214.
- Halaji M, Farahani A, Ranjbar R, Heiat M, Dehkordi FS. Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19. *Infez Med*. 2020;28(suppl):6-17.
- Sheikhshahrokh A, Ranjbar R, Saeidi E, Dehkordi FS, Heiat M, Ghasemi-Dehkordi P, Goodarzi H. Frontier therapeutics and vaccine strategies for sars-cov-2 (COVID-19): A review. *Iranian Journal of Public Health*. 2020 Oct;49(Suppl 1):18.
- Ranjbar R, Mahmoodzadeh Hosseini H, Safarpour Dehkordi F. A review on biochemical and immunological biomarkers used for laboratory diagnosis of SARS-CoV-2 (COVID-19). *The Open Microbiology Journal*. 2020 Dec 15;14(1).
- Rahi A, Kazemeini H, Jafariaskari S, Seif A, Hosseini S, Dehkordi FS. Genotypic and phenotypic-based assessment of antibiotic

- resistance and profile of staphylococcal cassette chromosome mec in the methicillin-resistant *Staphylococcus aureus* recovered from raw milk. *Infection and drug resistance*. 2020;13:273.
31. Muñoz-Ramírez ZY, Pascoe B, Mendez-Tenorio A, Mourkas E, Sandoval-Motta S, Perez-Perez G, Morgan DR, Dominguez RL, Ortiz-Princz D, Cavazza ME, Rocha G. A 500-year tale of co-evolution, adaptation, and virulence: *Helicobacter pylori* in the Americas. *The ISME journal*. 2021 Jan;15(1):78-92.
32. Ueda J, Yamaguchi A, Shibasaki K. Occurrence of *Helicobacter pylori* in saliva from preschool-age children. *Oral Science International*. 2015;12(1):5-8.
33. Fernández Tilapa G, Axinecuilteco Hilera J, Giono Cerezo S, Martínez Carrillo DN, Illades Aguiar B, Román Román A. *vacA* genotypes in oral cavity and *Helicobacter pylori* seropositivity among adults without dyspepsia. *Medicina Oral, Patología Oral, Cirugía Bucal*. 2011;16(2):e175-80.
34. Goud ES, Kannan R, Rao UK, Joshua E, Tavaraja R, Jain Y. Identification of *Helicobacter pylori* in saliva of patients with and without gastritis by polymerase chain reaction. *Journal of Pharmacy & Bioallied Sciences*. 2019;11(Suppl 3):S523.
35. Salari Z, Ranjkesh A, Behboudi E. Molecular Identification of *Helicobacter pylori* and *IceA* Genes Frequency from Dental Plaques Isolated from People Using PCR Method. *International Journal of Medical Laboratory*. 2020;7(3):191-196.
36. Cuyutupac G, Armando I. Dental Biofilm, a reservoir for *Helicobacter Pylori* in patients with chronic gastritis. *Revista de la Facultad de Medicina Humana*. 2020;20(4):597-601.
37. Yang J, Zhang Q, Chen M, Wu WZ, Wang R, Liu CJ, et al. Association Between *Helicobacter pylori* Infection and Risk of Periodontal Diseases in Han Chinese: A Case-Control Study. *Medical Science Monitor*
38. Rasmussen LT, Labio RW, Gatti LL, Silva LC, Queiroz VF, Smith MD, Payão SL. *Helicobacter pylori* detection in gastric biopsies, saliva and dental plaque of Brazilian dyspeptic patients. *Memorias do Instituto Oswaldo Cruz*. 2010;105:326-30.
39. Fauzia KA, Miftahussurur M, Syam AF, Waskito LA, Doohan D, Rezkitha YA, Matsumoto T, Tuan VP, Akada J, Yonezawa H, Kamiya S. Biofilm formation and antibiotic resistance phenotype of *Helicobacter pylori* clinical isolates. *Toxins*. 2020;12(8):473.
40. Hanafiah A, Binmaeil H, Ali RA, Rose IM, Lopes BS. Molecular characterization and prevalence of antibiotic resistance in *Helicobacter pylori* isolates in Kuala Lumpur, Malaysia. *Infection and Drug Resistance*. 2019;12:3051.
41. Mashak Z, Jafariaskari S, Alavi I, Shahreza MS, Dehkordi FS. Phenotypic and genotypic assessment of antibiotic resistance and genotyping of *vacA*, *cagA*, *iceA*, *oipA*, *cagE*, and *babA2* alleles of *Helicobacter pylori* bacteria isolated from raw meat. *Infection and Drug Resistance*. 2020;13:257.